Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667908 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06667908 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 130 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06667908, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- DRUG JNJ-90301900
- RADIATION Concurrent Chemo/Radiation Therapy (cCRT)
- DRUG Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
- DRUG Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Study Locations (20)
Other
- Royal Brisbane and Women's Hospital - Herston
- Sir Charles Gairdner Hospital - Nedlands
- Macquarie University - North Ryde
- Royal Melbourne Hospital - Parkville
- Fundacao Pio XII - Barretos
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes - São Paulo
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein - São Paulo
Connecticut
- University of Connecticut Health Center - Farmington
- Yale University - New Haven
Florida
- University of Miami - Miami
- Orlando Health Cancer Institute - Orlando
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- FirstHealth of the Carolinas - Pinehurst
Georgia
- Emory University Winship Cancer Institute - Atlanta
Oregon
- Oregon Health And Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06667908
The ClinicalTrials.gov registry entry for NCT06667908 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The listed sponsor is Johnson & Johnson Enterprise Innovation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.
NCT06667908 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT06667908 about?
NCT06667908 is a clinical study titled "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is compl...
What is the current status of trial NCT06667908?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2024-12-06. Estimated completion is 2028-12-31.
What conditions does trial NCT06667908 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06667908?
The interventions under investigation include: Durvalumab (BIOLOGICAL), JNJ-90301900 (DRUG), Concurrent Chemo/Radiation Therapy (cCRT) (RADIATION), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin (DRUG), Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06667908?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667908 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.